Index - P/E - EPS (ttm) -1.26 Insider Own 33.37% Shs Outstand 41.03M Perf Week 6.34%
Market Cap 30.63M Forward P/E - EPS next Y -0.99 Insider Trans -23.30% Shs Float 27.42M Perf Month -11.31%
Income -47.92M PEG - EPS next Q -0.29 Inst Own 34.81% Short Float 0.60% Perf Quarter -78.85%
Sales 10.09M P/S 3.04 EPS this Y 9.56% Inst Trans -0.35% Short Ratio 0.12 Perf Half Y -33.54%
Book/sh 1.86 P/B 0.40 EPS next Y 11.54% ROA -50.55% Short Interest 0.16M Perf Year -66.01%
Cash/sh 2.34 P/C 0.32 EPS next 5Y - ROE -66.10% 52W Range 0.67 - 5.95 Perf YTD -74.59%
Dividend Est. - P/FCF - EPS past 5Y -22.95% ROI -60.47% 52W High -87.49% Beta 2.50
Dividend TTM - Quick Ratio 4.18 Sales past 5Y 0.00% Gross Margin 98.18% 52W Low 10.92% ATR (14) 0.09
Dividend Ex-Date - Current Ratio 4.18 EPS Y/Y TTM 35.64% Oper. Margin -515.34% RSI (14) 28.82 Volatility 3.61% 5.08%
Employees 29 Debt/Eq 0.06 Sales Y/Y TTM - Profit Margin -474.96% Recom 2.43 Target Price 2.75
Option/Short Yes / Yes LT Debt/Eq 0.04 EPS Q/Q 48.72% Payout - Rel Volume 0.37 Prev Close 0.74
Sales Surprise 86.74% EPS Surprise 43.11% Sales Q/Q - Earnings Mar 13 AMC Avg Volume 1.37M Price 0.74
SMA20 2.43% SMA50 -64.35% SMA200 -66.17% Trades
Volume 503,244 Change 0.38%
Date
Action
Analyst
Rating Change
Price Target Change
Mar-14-24 Downgrade RBC Capital Mkts
Outperform → Sector Perform
$9 → $2
Mar-14-24 Downgrade Leerink Partners
Outperform → Market Perform
$9 → $2
Mar-14-24 Downgrade Ladenburg Thalmann
Buy → Neutral
Mar-14-24 Downgrade H.C. Wainwright
Buy → Neutral
Mar-14-24 Downgrade Guggenheim
Buy → Neutral
Feb-21-24 Initiated Guggenheim
Buy
$10
Dec-17-21 Initiated Oppenheimer
Outperform
$15
Dec-10-21 Initiated The Benchmark Company
Speculative Buy
$7
Nov-16-21 Downgrade SVB Leerink
Outperform → Mkt Perform
Jul-19-21 Initiated H.C. Wainwright
Buy
$30
Apr-26-21 Resumed Credit Suisse
Outperform
$26
Nov-03-20 Initiated SVB Leerink
Outperform
$35
Nov-03-20 Initiated RBC Capital Mkts
Outperform
$28
Nov-03-20 Initiated Credit Suisse
Outperform
$28
Nov-03-20 Initiated Cowen
Outperform
$44
Show Previous Ratings
May-01-24 04:05PM
Apr-30-24 04:05PM
Apr-22-24 04:05PM
Mar-27-24 12:00PM
Mar-21-24 10:20AM
08:28AM
Loading…
Mar-14-24 08:28AM
Mar-13-24 05:33PM
04:08PM
04:01PM
Jan-30-24 04:05PM
Jan-22-24 08:00AM
Jan-05-24 08:00AM
Jan-04-24 08:00AM
Nov-13-23 04:05PM
Nov-02-23 04:05PM
08:00AM
Loading…
Oct-18-23 08:00AM
Aug-28-23 04:00PM
Aug-14-23 04:00PM
Jul-24-23 12:00PM
Jun-12-23 04:00PM
May-25-23 08:00AM
May-24-23 04:05PM
May-22-23 09:30AM
May-16-23 06:18AM
May-15-23 08:00AM
May-04-23 04:05PM
May-02-23 04:05PM
Mar-31-23 12:00PM
Mar-16-23 04:00PM
Feb-28-23 04:05PM
10:43AM
Loading…
Feb-23-23 10:43AM
Feb-10-23 08:00AM
(American City Business Journals) -7.33%
Feb-09-23 08:00AM
Feb-01-23 04:05PM
Jan-31-23 09:55AM
Jan-09-23 08:05AM
Jan-06-23 05:54PM
(American City Business Journals) +93.60%
06:16AM
Jan-05-23 04:00PM
Nov-16-22 01:13PM
Nov-10-22 04:01PM
Oct-26-22 04:05PM
Aug-30-22 04:05PM
Aug-10-22 04:05PM
Jun-01-22 04:01PM
May-31-22 08:00AM
May-11-22 04:01PM
May-03-22 04:05PM
Apr-11-22 08:00AM
Mar-14-22 04:05PM
04:01PM
Mar-01-22 04:05PM
Feb-03-22 04:05PM
Jan-24-22 08:00AM
Jan-19-22 09:38PM
Jan-05-22 08:00AM
Dec-31-21 01:50PM
Dec-17-21 07:27AM
07:16AM
Dec-14-21 10:00AM
Nov-18-21 04:05PM
Nov-15-21 04:05PM
04:01PM
Sep-29-21 01:06PM
Sep-07-21 04:05PM
Aug-25-21 09:00AM
Aug-11-21 08:55AM
Aug-10-21 04:05PM
11:59AM
Jul-23-21 10:14AM
Jul-07-21 11:38AM
Jun-24-21 08:07AM
Jun-21-21 08:03AM
May-24-21 08:01AM
May-13-21 04:05PM
May-12-21 04:05PM
Mar-22-21 04:05PM
Mar-17-21 08:00AM
Mar-02-21 08:00AM
Feb-17-21 04:05PM
Jan-12-21 05:10AM
Jan-06-21 08:00AM
Dec-17-20 04:05PM
Nov-18-20 04:05PM
Nov-04-20 04:05PM
Oct-16-20 07:38PM
Oct-14-20 04:05PM
Oct-09-20 03:49PM
01:28PM
11:51AM
Spruce Biosciences, Inc. is a late-stage biopharmaceutical company, which engages in developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. It focuses on developing its wholly owned product candidate, Tildacerfont. The company was founded on November 13, 2014 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Novo Holdings A/S 10% Owner Mar 21 '24 Sale 0.75 465,021 350,951 2,550,000 Mar 25 09:45 PM Novo Holdings A/S 10% Owner Mar 20 '24 Sale 0.73 359,979 264,081 3,015,021 Mar 20 08:56 PM Novo Holdings A/S 10% Owner Mar 19 '24 Sale 0.76 593,000 447,715 3,375,000 Mar 20 08:56 PM Novo Holdings A/S 10% Owner Mar 18 '24 Sale 0.77 842,020 647,008 3,968,000 Mar 20 08:56 PM Novo Holdings A/S 10% Owner Mar 14 '24 Sale 0.89 1,912,316 1,698,902 4,810,020 Mar 18 09:14 PM Gharib Samir M. President & CFO Dec 15 '23 Option Exercise 0.00 112,250 0 204,403 Dec 18 08:16 PM Charlton Ralph William III Chief Medical Officer Dec 15 '23 Option Exercise 0.00 31,750 0 56,992 Dec 18 08:17 PM Szwarcberg Javier B. Chief Executive Officer Dec 15 '23 Option Exercise 0.00 111,000 0 145,705 Dec 18 08:15 PM
Index RUT P/E - EPS (ttm) -2.52 Insider Own 33.43% Shs Outstand 33.42M Perf Week 4.19%
Market Cap 58.15M Forward P/E - EPS next Y -0.56 Insider Trans 0.00% Shs Float 22.25M Perf Month 0.58%
Income -77.39M PEG - EPS next Q -0.44 Inst Own 48.17% Short Float 13.21% Perf Quarter 9.43%
Sales 0.00M P/S - EPS this Y 63.76% Inst Trans 0.31% Short Ratio 17.03 Perf Half Y -77.83%
Book/sh 2.65 P/B 0.66 EPS next Y 39.23% ROA -71.78% Short Interest 2.94M Perf Year -82.37%
Cash/sh 3.08 P/C 0.56 EPS next 5Y - ROE -82.07% 52W Range 0.98 - 9.96 Perf YTD 8.75%
Dividend Est. - P/FCF - EPS past 5Y -50.29% ROI -86.71% 52W High -82.53% Beta 0.23
Dividend TTM - Quick Ratio 5.87 Sales past 5Y 0.00% Gross Margin - 52W Low 77.53% ATR (14) 0.07
Dividend Ex-Date - Current Ratio 5.87 EPS Y/Y TTM -18.83% Oper. Margin 0.00% RSI (14) 57.35 Volatility 3.23% 4.28%
Employees 8 Debt/Eq 0.01 Sales Y/Y TTM - Profit Margin - Recom 3.33 Target Price 1.10
Option/Short Yes / Yes LT Debt/Eq 0.01 EPS Q/Q -26.88% Payout - Rel Volume 0.64 Prev Close 1.73
Sales Surprise - EPS Surprise -21.11% Sales Q/Q - Earnings Mar 28 BMO Avg Volume 172.67K Price 1.74
SMA20 2.49% SMA50 4.25% SMA200 -60.71% Trades
Volume 110,683 Change 0.58%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-15-23 Downgrade Leerink Partners
Outperform → Market Perform
Dec-15-23 Downgrade Jefferies
Buy → Hold
Dec-15-23 Downgrade H.C. Wainwright
Buy → Neutral
$30 → $1.50
Dec-14-23 Downgrade William Blair
Outperform → Mkt Perform
Dec-14-23 Downgrade Robert W. Baird
Outperform → Neutral
$28 → $3
Dec-14-23 Downgrade Piper Sandler
Overweight → Neutral
$25 → $4
Dec-14-23 Downgrade Ladenburg Thalmann
Buy → Neutral
Dec-14-23 Downgrade BofA Securities
Buy → Underperform
$23 → $1.45
Nov-15-23 Initiated William Blair
Outperform
$35.55
Aug-28-23 Initiated H.C. Wainwright
Buy
$30
Jul-03-23 Initiated BofA Securities
Buy
Sep-19-22 Resumed H.C. Wainwright
Buy
$31
Jan-27-22 Initiated Robert W. Baird
Outperform
$28
Dec-21-21 Initiated H.C. Wainwright
Buy
$28
Nov-22-21 Initiated Ladenburg Thalmann
Buy
$45
May-04-21 Initiated SVB Leerink
Outperform
$25
May-04-21 Initiated Piper Sandler
Overweight
$45
May-04-21 Initiated Jefferies
Buy
$24
Show Previous Ratings
Mar-28-24 12:53PM
07:35AM
Mar-25-24 07:00AM
Dec-21-23 04:13PM
Dec-15-23 10:19AM
12:35PM
Loading…
Dec-14-23 12:35PM
09:05AM
Nov-13-23 05:04PM
07:35AM
Nov-02-23 07:50AM
Oct-25-23 07:50AM
Oct-20-23 01:22PM
Oct-09-23 07:50AM
Oct-06-23 08:30AM
Aug-29-23 07:35AM
07:35AM
Loading…
Aug-10-23 07:35AM
07:31AM
Jul-27-23 11:19AM
Jun-30-23 08:25AM
Jun-26-23 08:25AM
Jun-15-23 12:44PM
May-31-23 10:38AM
08:00AM
May-21-23 07:42PM
May-12-23 06:00PM
May-11-23 07:45AM
May-03-23 11:36PM
04:01PM
Mar-27-23 07:30AM
Mar-14-23 07:30AM
08:00AM
Loading…
Mar-09-23 08:00AM
Mar-03-23 06:07AM
Feb-02-23 07:35AM
Jan-31-23 07:35AM
Dec-04-22 07:12AM
Nov-08-22 07:35AM
Nov-03-22 08:00AM
Sep-14-22 06:02AM
Sep-06-22 08:35AM
Aug-29-22 07:35AM
Aug-09-22 08:00AM
Aug-04-22 09:10AM
(Simply Wall St.) +14.89%
Aug-02-22 07:30AM
Jul-26-22 09:52AM
07:30AM
Jul-11-22 08:00AM
Jun-30-22 08:00AM
Jun-20-22 08:33AM
May-10-22 04:05PM
Mar-23-22 04:05PM
Mar-07-22 08:30AM
Feb-02-22 08:00AM
Jan-24-22 08:00AM
Jan-10-22 11:55AM
Dec-22-21 11:04AM
Nov-11-21 04:05PM
Nov-01-21 04:05PM
Oct-14-21 08:00AM
Oct-11-21 02:35PM
08:00AM
Sep-28-21 08:26AM
Sep-09-21 09:12AM
Aug-11-21 05:55AM
Jul-28-21 08:00AM
Jul-12-21 09:30AM
Jul-09-21 08:00AM
Jul-07-21 08:00AM
Jun-29-21 08:00AM
May-20-21 06:00AM
May-19-21 06:00AM
Apr-13-21 08:14AM
Apr-09-21 12:32PM
Apr-08-21 09:42PM
Reneo Pharmaceuticals, Inc. is a clinical-stage company, which engages in the research and development of therapies for rare genetic mitochondrial diseases. The company was founded by Michael G. Grey and Niall O'Donnell on September 22, 2014 and is headquartered in San Diego, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Hall Ashley Chief Development Officer Aug 28 '23 Option Exercise 1.80 15,625 28,125 55,225 Aug 29 05:04 PM Hall Ashley Chief Development Officer Aug 28 '23 Sale 6.28 15,625 98,058 39,600 Aug 29 05:04 PM Novo Holdings A/S 10% Owner Jun 23 '23 Sale 7.10 100,000 709,740 3,330,337 Jun 23 07:15 PM O'Donnell Niall Director May 08 '23 Buy 8.00 125,000 1,000,000 2,188,713 May 10 05:47 PM
Index RUT P/E - EPS (ttm) -4.03 Insider Own 21.46% Shs Outstand 46.72M Perf Week 5.64%
Market Cap 1.22B Forward P/E 69.30 EPS next Y 0.37 Insider Trans -0.30% Shs Float 37.00M Perf Month 2.01%
Income -160.91M PEG - EPS next Q -0.42 Inst Own 91.03% Short Float 23.18% Perf Quarter -2.56%
Sales 186.37M P/S 6.53 EPS this Y 70.84% Inst Trans 11.41% Short Ratio 17.31 Perf Half Y -9.08%
Book/sh 5.32 P/B 4.86 EPS next Y 132.46% ROA -32.20% Short Interest 8.58M Perf Year -9.62%
Cash/sh 6.08 P/C 4.25 EPS next 5Y - ROE -82.37% 52W Range 23.14 - 35.56 Perf YTD -12.47%
Dividend Est. - P/FCF - EPS past 5Y -39.57% ROI -28.95% 52W High -27.33% Beta 1.13
Dividend TTM - Quick Ratio 4.19 Sales past 5Y 88.90% Gross Margin 75.98% 52W Low 11.67% ATR (14) 0.99
Dividend Ex-Date - Current Ratio 4.45 EPS Y/Y TTM -0.28% Oper. Margin -57.22% RSI (14) 56.18 Volatility 4.10% 3.89%
Employees 264 Debt/Eq 1.24 Sales Y/Y TTM 141.85% Profit Margin -86.33% Recom 1.10 Target Price 50.50
Option/Short Yes / Yes LT Debt/Eq 1.23 EPS Q/Q 28.44% Payout - Rel Volume 0.69 Prev Close 25.60
Sales Surprise 2.49% EPS Surprise -162.39% Sales Q/Q 149.24% Earnings Feb 28 AMC Avg Volume 495.35K Price 25.84
SMA20 4.06% SMA50 -1.45% SMA200 -7.98% Trades
Volume 341,057 Change 0.94%
Date
Action
Analyst
Rating Change
Price Target Change
Apr-17-24 Initiated Stifel
Buy
$48
Dec-18-23 Reiterated H.C. Wainwright
Buy
$60 → $58
Nov-20-23 Resumed JP Morgan
Overweight
$37
Nov-13-23 Initiated Morgan Stanley
Overweight
$60
Oct-24-23 Initiated Cantor Fitzgerald
Overweight
$50
Oct-17-23 Resumed Evercore ISI
Outperform
$62
Sep-20-23 Initiated JMP Securities
Mkt Outperform
$70
Sep-01-22 Initiated Citigroup
Buy
$38
Sep-20-21 Initiated JP Morgan
Overweight
$30
Aug-07-20 Upgrade Raymond James
Outperform → Strong Buy
$28 → $48
Aug-03-20 Initiated H.C. Wainwright
Buy
$52
Jul-31-20 Initiated Piper Sandler
Overweight
$77
Jun-25-20 Initiated Robert W. Baird
Outperform
$30
Aug-12-19 Initiated ROTH Capital
Buy
$33
Aug-12-19 Initiated Raymond James
Outperform
$28
Aug-12-19 Initiated Guggenheim
Buy
$18
Aug-12-19 Initiated Evercore ISI
Outperform
Aug-12-19 Initiated Citigroup
Buy
$21
Show Previous Ratings
May-02-24 02:33PM
May-01-24 04:10PM
Apr-25-24 10:02AM
Apr-10-24 09:30PM
Apr-02-24 08:30AM
11:30AM
Loading…
Mar-29-24 11:30AM
Mar-25-24 11:46PM
07:00AM
Mar-15-24 09:32AM
Mar-13-24 06:00PM
Mar-08-24 07:30PM
Mar-05-24 08:00AM
Feb-29-24 11:34AM
09:49AM
08:30AM
05:35PM
Loading…
Feb-28-24 05:35PM
04:38PM
04:03PM
Feb-21-24 04:05PM
Feb-09-24 09:15PM
Feb-05-24 07:00AM
Jan-23-24 11:44AM
Jan-19-24 09:30PM
Jan-16-24 08:30AM
Jan-15-24 04:03AM
Jan-10-24 07:00PM
Jan-08-24 08:30AM
Jan-03-24 08:45AM
Dec-18-23 01:05PM
(Associated Press Finance) -15.87%
08:37AM
08:30AM
Loading…
08:30AM
Dec-08-23 07:30PM
Nov-30-23 09:45AM
Nov-20-23 04:05PM
Nov-13-23 02:00PM
Nov-10-23 05:30PM
Nov-06-23 09:10AM
Nov-03-23 08:30AM
Nov-02-23 07:13PM
04:05PM
Oct-30-23 10:00AM
08:30AM
Oct-27-23 08:45AM
Oct-17-23 04:30PM
Oct-11-23 04:52PM
Oct-10-23 08:00PM
Oct-07-23 05:00PM
Oct-02-23 08:30AM
Sep-26-23 08:30AM
Sep-21-23 08:30AM
Sep-15-23 03:05PM
08:30AM
06:01AM
Sep-14-23 01:15PM
Sep-13-23 01:01PM
Sep-11-23 10:07AM
Sep-08-23 11:30PM
Sep-06-23 11:19AM
08:30AM
Sep-05-23 08:30AM
08:30AM
Aug-10-23 07:00PM
Aug-03-23 05:25PM
04:05PM
Jul-27-23 04:05PM
Jul-25-23 05:12PM
08:30AM
Jul-20-23 08:18AM
Jul-18-23 10:48AM
(American City Business Journals)
Jul-17-23 02:18PM
08:00AM
08:00AM
Jul-10-23 08:00PM
Jun-29-23 09:27AM
Jun-23-23 12:00PM
Jun-14-23 08:30AM
Jun-09-23 09:30PM
Jun-07-23 08:30AM
Jun-02-23 08:49AM
May-19-23 07:00AM
May-18-23 08:30AM
May-17-23 08:30AM
May-11-23 08:30AM
May-10-23 09:00PM
May-09-23 02:59PM
May-06-23 08:05AM
May-04-23 06:05PM
04:02PM
May-01-23 10:00AM
Apr-27-23 04:02PM
10:02AM
Apr-25-23 05:44AM
Apr-18-23 06:15AM
Apr-13-23 12:15AM
Apr-12-23 07:00AM
06:59AM
Apr-10-23 08:30PM
Apr-06-23 08:30AM
Apr-05-23 08:30AM
Apr-02-23 11:36AM
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products include Maralixibat and Volixibat. The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Mar 27 '24 Buy 24.80 2,000 49,600 14,000 Mar 27 08:47 PM Radovich Peter PRESIDENT AND COO Mar 25 '24 Sale 25.80 4,303 111,017 29,013 Mar 25 05:41 PM BJERKHOLT ERIC CHIEF FINANCIAL OFFICER Mar 18 '24 Buy 25.80 2,000 51,600 12,000 Mar 18 05:34 PM Peetz Christopher CHIEF EXECUTIVE OFFICER Feb 02 '24 Sale 26.19 6,013 157,491 104,112 Feb 05 09:04 PM Radovich Peter PRESIDENT AND COO Feb 02 '24 Sale 26.19 1,790 46,883 34,695 Feb 05 09:05 PM Vig Pamela CHIEF SCIENTIFIC OFFICER Feb 02 '24 Sale 26.19 1,214 31,797 28,691 Feb 05 09:12 PM Longpre Lara CHIEF DEVELOPMENT OFFICER Feb 02 '24 Sale 26.19 847 22,184 104,407 Feb 05 09:10 PM Howe Jolanda SVP, GLOBAL CONTROLLER Feb 02 '24 Sale 26.19 735 19,251 1,759 Feb 02 09:28 PM Peetz Christopher PRESIDENT AND CEO Jan 08 '24 Sale 28.03 5,209 146,033 110,125 Jan 09 08:12 PM Radovich Peter CHIEF OPERATING OFFICER Jan 08 '24 Sale 28.03 1,408 39,473 36,485 Jan 09 08:28 PM Vig Pamela HEAD OF RESEARCH & DEVELOPMENT Jan 08 '24 Sale 28.03 1,408 39,472 29,905 Jan 09 08:21 PM Longpre Lara CHIEF DEVELOPMENT OFFICER Jan 08 '24 Sale 28.04 1,019 28,568 105,254 Jan 09 08:25 PM Howe Jolanda SVP, GLOBAL CONTROLLER Jan 08 '24 Sale 28.04 528 14,803 722 Jan 09 08:09 PM Howe Jolanda SVP, Global Controller Dec 05 '23 Option Exercise 2.94 2,500 7,350 2,500 Dec 06 05:16 PM Howe Jolanda SVP, Global Controller Dec 05 '23 Sale 32.40 2,500 81,000 0 Dec 06 05:16 PM GREY MICHAEL G Director Sep 14 '23 Option Exercise 2.94 14,216 41,738 14,216 Sep 14 07:33 PM GREY MICHAEL G Director Sep 14 '23 Sale 32.00 14,216 454,912 0 Sep 14 07:33 PM GREY MICHAEL G Director Sep 13 '23 Option Exercise 2.94 392 1,151 392 Sep 14 07:33 PM Heron Patrick J Director Sep 13 '23 Buy 31.02 2,625 81,425 159,053 Sep 15 04:56 PM GREY MICHAEL G Director Sep 13 '23 Sale 32.00 392 12,544 0 Sep 14 07:33 PM Heron Patrick J Director Sep 12 '23 Buy 30.60 3,750 114,764 156,428 Sep 13 04:39 PM BJERKHOLT ERIC Chief Financial Officer Sep 11 '23 Buy 29.65 10,000 296,492 10,000 Sep 12 06:23 PM Heron Patrick J Director Sep 11 '23 Buy 30.30 4,687 142,027 152,678 Sep 13 04:39 PM Heron Patrick J Director Aug 31 '23 Buy 26.25 147,991 3,884,764 147,991 Sep 05 12:51 PM Howe Jolanda SVP, Global Controller Aug 25 '23 Sale 26.23 3,459 90,743 0 Aug 28 04:30 PM Peetz Christopher President and CEO Jul 03 '23 Sale 25.65 5,498 141,005 115,334 Jul 05 07:30 PM Radovich Peter Chief Operating Officer Jul 03 '23 Sale 25.65 1,425 36,546 37,675 Jul 05 07:47 PM Vig Pamela Head of Research & Development Jul 03 '23 Sale 25.65 1,425 36,546 30,786 Jul 05 07:35 PM Longpre Lara Chief Development Officer Jul 03 '23 Sale 25.65 1,004 25,749 105,839 Jul 05 07:37 PM Howe Jolanda SVP, Global Controller Jul 03 '23 Sale 25.65 915 23,467 3,459 Jul 05 07:33 PM GREY MICHAEL G Director Jun 08 '23 Option Exercise 2.94 14,608 42,889 14,608 Jun 09 04:20 PM GREY MICHAEL G Director Jun 08 '23 Sale 29.00 14,608 423,632 0 Jun 09 04:20 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
